Dashboard
Manage Tickers

PCRX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

pacira-biosciences-completes-patient-enrollment-for-part-a-of-its-phase-2-ascend-trial-evaluating-pcrx-201-a-locally-administered-gene-therapy-for-knee-osteoarthritis
Pacira BioSciences Completes Patient Enrol...
11/05/2025 13:06:19

Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies...

pacira-biosciences-inks-exclusive-worldwide-license-and-collaboration-agreement-with-amacathera--for-amt-143-a-non-opioid-analgesic-ropivacaine-for-postsurgical-pain-control-amacathera-will-receive-an-upfront-payment-of-5m-with-potential-for-milestone-payments-and-sales-based-royalty
Pacira Biosciences Inks Exclusive Worldwid...
11/04/2025 12:15:24

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies ...

pacira-biosciences-presents-updated-three-year-data-on-pcrx-201-gene-therapy-in-patients-with-moderate-to-severe-osteoarthritis-of-the-knee-showing-clinical-improvements-for-up-to-156-weeks-following-single-administration
Pacira BioSciences Presents Updated Three-...
10/28/2025 12:13:54

pacira-biosciences-receives-paragraph-iv-certification-notice-letter-from-qilu-pharmaceutical-qilu-has-filed-abbreviated-new-drug-application-for-product-claiming-to-be-generic-equivalent-of-exparel-pacira-says-intents-to-assert-its-ip-rights
Pacira BioSciences Receives Paragraph IV C...
10/27/2025 12:14:17

pacira-biosciences-to-present-real-world-evidence-evaluating-clinical-effectiveness-and-economic-benefits-of-exparel-at-amcp-nexus-2025-annual-meeting
Pacira BioSciences To Present Real-World E...
10/23/2025 12:02:36

-- Findings Presented at AMCP Nexus 2025 Annual Meeting --BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioScience...

pacira-biosciences-receives-paragraph-iv-notice-letter-for-exparel-from-whiteoak-group-subsidiary-of-zhejiang-haichang
Pacira BioSciences Receives Paragraph IV N...
10/21/2025 12:34:34

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies ...

paccar-posts-downbeat-earnings-joins-neuphoria-therapeutics-citius-pharmaceuticals-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
PACCAR Posts Downbeat Earnings, Joins Neup...
10/21/2025 12:16:10

pacira-biosciences-to-present-new-data-from-phase-1-clinical-trial-evaluating-pcrx-201-gene-therapy-candidate-for-osteoarthritis-of-knee-at-acr-convergence-2025-meeting
Pacira Biosciences To Present New Data Fro...
10/20/2025 20:03:42

pacira-biosciences-narrows-fy2025-sales-guidance-from-725000m-765000m-to-730000m-750000m-vs-739059m-est
Pacira BioSciences Narrows FY2025 Sales Gu...
08/05/2025 20:02:06

Pacira BioSciences (NASDAQ:PCRX) narrows FY2025 sales outlook from $725.000 million-$765.000 million to $730.000 million-$750.0...

pacira-biosciences-q2-adj-eps-074-beats-068-estimate-sales-181099m-miss-183330m-estimate
Pacira BioSciences Q2 Adj. EPS $0.74 Beats...
08/05/2025 20:01:14

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

insights-ahead-pacira-biosciencess-quarterly-earnings
Insights Ahead: Pacira BioSciences's Quart...
08/04/2025 19:08:09

pacira-biosciences-collaborates-with-johnson--johnson-medtech-to-expand-market-reach-of-zilretta-leveraging-early-intervention-sales-force-to-co-promote-treatment-to-existing-and-new-customers
Pacira BioSciences Collaborates With Johns...
07/22/2025 12:03:23

Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient accessBRISBA...

pacira-biosciences-announces-reorganization-shuts-down-45-liter-facility-and-reduces-workforce-by-7
Pacira Biosciences Announces Reorganizatio...
07/10/2025 11:39:01

pacira-biosciences-announces-phase-1-data-showing-single-injection-of-gene-therapy-pcrx-201-provides-sustained-pain-stiffness-and-function-improvement-in-knee-osteoarthritis-patients-for-up-to-3-years
Pacira BioSciences Announces Phase 1 Data ...
06/11/2025 12:11:44

-- PCRX-201 demonstrated sustained clinical efficacy with improvements in pain, stiffness, and function for up to three years –...

pacira-biosciences-new-preliminary-data-suggests-clinical-immunogenicity-does-not-reduce-sustained-improvements-in-knee-pain-stiffness-and-function-provided-by-gene-therapy-candidate-pcrx-201
Pacira Biosciences: New Preliminary Data S...
05/15/2025 12:13:16

-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the saf...

where-pacira-biosciences-stands-with-analysts
Where Pacira BioSciences Stands With Analysts
05/09/2025 13:00:31

needham-maintains-buy-on-pacira-biosciences-lowers-price-target-to-30
Needham Maintains Buy on Pacira BioScience...
05/09/2025 12:47:59

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $32 to...

pacira-biosciences-affirms-fy2025-sales-guidance-of-72500m-76500m-vs-75221m-est
Pacira BioSciences Affirms FY2025 Sales Gu...
05/08/2025 20:01:45

Pacira BioSciences (NASDAQ:PCRX) affirms FY2025 sales outlook from $725.00 million-$765.00 million to $725.00 million-$765.00 m...

pacira-biosciences-q1-adj-eps-062-beats-060-estimate-sales-16892m-miss-17603m-estimate
Pacira BioSciences Q1 Adj. EPS $0.62 Beats...
05/08/2025 20:01:13

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION